The clearance adds a Centiloid scale tool to GE Healthcare’s Mim software to help clinicians determine the density of amyloid ...

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...

This approval marks a breakthrough for individuals diagnosed with hormone receptor-positive (HR+)/HER2-negative stage II and ...

Goldman Sachs analyst James Quigley maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...

Novartis Pharma AG, affiliated to Swiss drug major Novartis AG (NVS), announced Monday updated analysis from the pivotal Phase III ...

Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.

The increasing resistance to intravenous artemisinin therapy for malaria highlights the urgent need for new treatments that offer better patient compliance and a single-dose cure to address this ...

Novartis CEO boss Narishiman stated that the company will not compete in the weight loss drug market frenzy dominated by Novo ...

Over the past week, a Cambridge company won funding from ARPA-H for personalized regenerative cells, and two Massachusetts medical device companies announced funding rounds.